| Symbol | OCGN |
|---|---|
| Name | OCUGEN, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 11 GREAT VALLEY PARKWAY, MALVERN, Pennsylvania, 19355, United States |
| Telephone | +1 484 - 328-4701 |
| Fax | — |
| — | |
| Website | https://www.ocugen.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001372299 |
| Description | Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug one to many and novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. The company is co-developing Bharat Biotechs COVAXIN vaccine candidate for COVID-19 in the U.S. and Canadian markets. Additional info from NASDAQ: |
Director Kompella Uday 🟢 acquired 170.1K shares (1 derivative) of Ocugen, Inc. (OCGN) at $1.22 Transaction Date: Jun 11, 2026 | Filing ID: 074078
Read moreDirector Chandrasekhar Satishchandran 🟢 acquired 170.1K shares (1 derivative) of Ocugen, Inc. (OCGN) at $1.22 Transaction Date: Jun 11, 2026 | Filing ID: 074076
Read moreDirector Castillo Kirsten 🟢 acquired 170.1K shares (1 derivative) of Ocugen, Inc. (OCGN) at $1.22 Transaction Date: Jun 11, 2026 | Filing ID: 074073
Read moreDirector Zhang Junge 🟢 acquired 170.1K shares (1 derivative) of Ocugen, Inc. (OCGN) at $1.22 Transaction Date: Jun 11, 2026 | Filing ID: 074072
Read moreOcugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes
Read more